Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

Similar articles for PubMed (Select 23717018)

1.

Psoriasis induced by trastuzumab (herceptin®).

Kim DH, Jeong NJ, Im M, Lee Y, Seo YJ, Lee JH.

Ann Dermatol. 2013 May;25(2):229-31. doi: 10.5021/ad.2013.25.2.229. Epub 2013 May 10.

3.

[Trastuzumab (herceptin) for the medical treatment of breast cancer].

Bayoudh L, Afrit M, Daldoul O, Zarrad M, Boussen H.

Tunis Med. 2012 Jan;90(1):6-12. Review. French.

4.
5.

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J.

Cancer Res. 2001 Jun 15;61(12):4744-9.

6.

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.

Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C.

Breast Cancer Res Treat. 2009 Nov;118(1):113-24. doi: 10.1007/s10549-009-0412-3. Epub 2009 May 5.

PMID:
19415485
7.

Tufted hair folliculitis in a woman treated with trastuzumab.

Rosman IS, Anadkat MJ.

Target Oncol. 2010 Dec;5(4):295-6. doi: 10.1007/s11523-010-0162-5. Epub 2010 Oct 15.

PMID:
20949375
9.

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.

Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. Review.

PMID:
10482195
10.

Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.

Fischgräbe J, Götte M, Michels K, Kiesel L, Wülfing P.

Int J Cancer. 2010 Aug 1;127(3):696-706. doi: 10.1002/ijc.25076.

PMID:
19960438
11.
13.

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L.

Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83.

PMID:
10482197
15.

In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.

Chen KT, Lee TW, Lo JM.

Nucl Med Biol. 2009 May;36(4):355-61. doi: 10.1016/j.nucmedbio.2009.01.006. Epub 2009 Mar 26.

PMID:
19423002
16.

Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.

Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, Majumdar AP.

Mol Cancer Ther. 2005 Mar;4(3):435-42.

19.

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.

Int J Oncol. 2010 Sep;37(3):669-78.

PMID:
20664936
20.

A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.

Scollard DA, Chan C, Holloway CM, Reilly RM.

Nucl Med Biol. 2011 Jan;38(1):129-36. doi: 10.1016/j.nucmedbio.2010.06.010. Epub 2010 Sep 1.

PMID:
21220136
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk